Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
59 Dementia Trials near Albany, GA
Power is an online platform that helps thousands of Dementia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerONO-2020 for Alzheimer's Disease
Decatur, Georgia
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:55 - 85
Key Eligibility Criteria
Disqualifiers:Stroke, Schizophrenia, HIV, Others
Must Be Taking:Acetylcholinesterase Inhibitors, Memantine
240 Participants Needed
Citicoline Supplement for Mild Cognitive Impairment
Atlanta, Georgia
This trial is testing whether a citicoline supplement can help people with mild cognitive impairment (MCI). Citicoline may improve brain function by increasing important brain chemicals. Researchers will also check if it affects sleep and markers related to Alzheimer's disease. Citicoline has been studied for its potential benefits in cognitive decline, including Alzheimer's disease and vascular cognitive impairment.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:60+
Key Eligibility Criteria
Disqualifiers:Epilepsy, Cardiac Insufficiency, Diabetes, Others
Must Not Be Taking:REM Sleep Medications, Choline Supplements
100 Participants Needed
Emraclidine for Elderly Healthy Subjects
Decatur, Georgia
This trial is testing the safety of a drug called emraclidine, which is taken by mouth, in elderly people.
Trial Details
Trial Status:Active Not Recruiting
Age:65 - 85
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Cardiovascular Disease, Others
Must Be Taking:Cholinesterase Inhibitors, Memantine
17 Participants Needed
GSK4527226 for Early Alzheimer's Disease
Decatur, Georgia
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 85
Key Eligibility Criteria
Disqualifiers:Stroke, CNS Trauma, Alcohol Use, Others
Must Not Be Taking:Antipsychotics, Antidepressants, Opiates, Others
367 Participants Needed
LY3954068 for Alzheimer's Disease
Decatur, Georgia
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.
The study will be comprised of two parts, A and B. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. Each participant in Part B will receive 2 doses of either LY3954068 or placebo administered into the spinal fluid. Participants will have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068.
The study will last up to approximately 45 weeks for Part A, and 100 weeks for Part B, including the screening period.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:50 - 85
Key Eligibility Criteria
Disqualifiers:Serious Illnesses, MRI Contraindications, Others
Must Not Be Taking:Amyloid Therapies, Anti-tau Therapies
48 Participants Needed
ADEL-Y01 for Alzheimer's Disease
Decatur, Georgia
This is a Phase Ia/Ib, two-part, randomized, placebo-controlled, double-blinded, first in human(FIH) study to evaluate the safety, tolerability, PK, and PD of ADEL-Y01 in healthy participants in Part 1 and participants with MCI due to AD and mild AD in Part 2. The study includes 2 parts: Part 1 (single ascending dose \[SAD\] and Part 2 (multiple ascending dose \[MAD\]).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Cancer, Renal Failure, Infections, Others
Must Be Taking:Cholinesterase Inhibitors, Memantine
73 Participants Needed
Trontinemab for Alzheimer's Disease
Decatur, Georgia
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 90
Key Eligibility Criteria
Disqualifiers:Cerebrovascular Disease, CNS Trauma, Others
800 Participants Needed
Caring While Black Program for Caregiver Burden
Atlanta, Georgia
The goal of this project is to revise and test an online education program designed to enhance the mastery of Black American caregivers to provide care to family members or friends living with a dementia illness.
This study has two phases, and participants will take part in Phase 1 and/or Phase 2 of this study. Participants will take part in one and/or both phases in this study if they are a caregiver to a person living with dementia. Caregivers must self-identify as Black American and as the unpaid principal caregiver of a community-dwelling person living with a dementia illness and who is the principal companion of that person during healthcare encounters. Caregivers must also be 18 years of age or older and will be providing at least some hands-on care multiple times a week, if not daily. It is preferred that participants have access to and the ability to use broadband internet services to engage with the Caregiving While Black course. Participants should not have a plan in place to move the person living with a dementia illness to an institutional setting within the next six months.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Under 18, Prisoners, Cognitively Impaired, Others
140 Participants Needed
NMRA-323511 for Agitation in Alzheimer's Disease
Atlanta, Georgia
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly.
Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.
Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment.
Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:55 - 90
Key Eligibility Criteria
Disqualifiers:Epilepsy, Suicidal, Neurologic Disorder, Others
Must Not Be Taking:Anticonvulsants
96 Participants Needed
Screening for Alzheimer's Disease Studies
Decatur, Georgia
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 90
Key Eligibility Criteria
Disqualifiers:Neurological Conditions, CNS Trauma, Others
13000 Participants Needed
Trontinemab for Alzheimer's Disease
Decatur, Georgia
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 90
Key Eligibility Criteria
Disqualifiers:Cerebrovascular Disease, CNS Trauma, Others
800 Participants Needed
This trial tests two drugs, lecanemab and E2814, in people with a genetic mutation that causes Alzheimer's disease. Lecanemab helps remove harmful protein clumps from the brain, while E2814 prevents harmful protein tangles from forming. The goal is to see if these drugs can slow down or improve symptoms of Alzheimer's.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:Neurologic, Psychiatric, Substance Use, Others
Must Not Be Taking:Anticoagulants, Monoclonal Antibodies
197 Participants Needed
Disease-Modifying Drugs for Alzheimer's Disease
Atlanta, Georgia
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:Alcohol/drug Dependence, Cardiovascular Disease, Others
Must Not Be Taking:Anticoagulants, Monoclonal Antibodies
490 Participants Needed
Neflamapimod for Lewy Body Dementia
Atlanta, Georgia
This trial is testing neflamapimod, a drug that may help improve thinking and memory skills. It targets people with Dementia with Lewy Bodies (DLB), who often struggle with these issues. The drug works by reducing inflammation in the brain.
Trial Details
Trial Status:Active Not Recruiting
Age:55+
Key Eligibility Criteria
Disqualifiers:Not Listed
160 Participants Needed
AL001 for Frontotemporal Dementia
Atlanta, Georgia
This trial is testing AL001, a drug given through an IV, to see if it can help people with a genetic mutation that causes frontotemporal dementia. The goal is to find out if AL001 can improve brain health in these individuals.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:25 - 85
Key Eligibility Criteria
Disqualifiers:Alzheimer's, Parkinson's, Cancer, Others
Must Not Be Taking:Anticoagulants
110 Participants Needed
Decision Support for Dementia Caregivers
Atlanta, Georgia
The purpose of this study is to design and test a decision-making program that is tailored to support adult daughters making healthcare decisions for their parents who are living with memory loss to improve the quality of life of African American families.
There are two phases of this research study. The first phase will collect information by surveys and/or interviews. The surveys and interviews will ask questions about demographics (e.g., age, race/ethnicity), culture, health, family dynamics, caregiving, and healthcare experiences. The surveys will be completed by all eligible adult daughters and parents with memory loss in pairs. The interviews will be completed by a smaller number of pairs and by all former adult daughter caregivers.
The general scope of topics is caregiving experiences, cultural identity, healthcare decisions for persons living with Alzheimer's disease, and related dementias, health, and well-being. The research team will identify and examine key factors that will lead to designing and testing the feasibility of a culturally tailored prototype intervention for African American dementia dyads/families of persons living with mild to moderate Alzheimer's disease and related dementias.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Parkinson's, Schizophrenia, Others
40 Participants Needed
Suvecaltamide for Tremors in Parkinson's Disease
Atlanta, Georgia
This trial tests suvecaltamide, a medication aimed at reducing severe tremors in adults with Parkinson's disease whose current treatments are not effective. The medication likely helps by calming the overactive nerves or muscles responsible for the tremors.
Trial Details
Trial Status:Recruiting
Age:40 - 85
Key Eligibility Criteria
Disqualifiers:Not Listed
160 Participants Needed
Cognitive Training for Mild Cognitive Impairment
Gainesville, Florida
Older adults at risk for dementia show a variety of cognitive deficits, which can be ameliorated by different cognitive training (CT) exercises. The best combination of CT exercises is unknown. The aim is to discover the most efficacious combination of CT exercises as compared to cognitive stimulation (which will serve as a stringent, active control) to modify the functional trajectories of older adults' with MCI, who are at high risk for dementia. The primary objective of the U01 phase was to design and pilot-test an adaptive, randomized clinical trial (RCT) of cognitive training (CT) combinations aimed to enhance performance of instrumental activities of daily living (IADL) among persons with mild cognitive impairment (MCI). In the R01 phase, the objective is to identify the best combination of CT exercises to delay dementia onset among persons with MCI. The longitudinal endpoint goal is reducing incident dementia. The primary aim of the study is to determine which CT combination has the best probability to delay dementia by producing the largest IADL improvements. The study further aims to explore neuroimaging and novel blood-based biomarkers.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:55 - 89
Key Eligibility Criteria
Disqualifiers:Dementia, Stroke, Parkinson's, Others
1305 Participants Needed
AVP-786 for Agitation in Alzheimer's Disease
Jacksonville, Florida
This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50 - 90
Key Eligibility Criteria
Disqualifiers:Non-Alzheimer's Dementia, Unstable Systemic Diseases, Myasthenia Gravis, Others
183 Participants Needed
Metformin for ALS
Gainesville, Florida
This trial is testing if Metformin, a diabetes drug, is safe and effective for patients with C9orf72 ALS. The drug aims to block harmful proteins linked to their genetic mutation. Metformin has been used to treat type 2 diabetes for more than 60 years and is currently being investigated for its potential anticancer effects.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Renal Disease, Liver Disease, Cancer, Others
Must Be Taking:Metformin
41 Participants Needed
Why Other Patients Applied
"I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."
OF
Alzheimer's Disease PatientAge: 65
"I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."
WU
Healthy Volunteer PatientAge: 76
"I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."
AH
Dementia PatientAge: 64
"I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."
VL
Alzheimer's PatientAge: 71
"I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."
EK
Mild Cognitive Impairment PatientAge: 72
Flortaucipir Imaging for Lewy Body Disease
Jacksonville, Florida
The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Multiple Sclerosis, Brain Tumors, Others
135 Participants Needed
tDCS for Cognitive Impairment
Gainesville, Florida
The current study is a mechanistic study to evaluate working memory gains from application of transcranial direct current stimulation (tDCS) in older adults with mild cognitive impairments (MCI) compared to cognitively healthy control
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:60 - 95
Key Eligibility Criteria
Disqualifiers:Neurological Disorders, Seizures, Psychiatric Disorders, Cancer, Others
Must Not Be Taking:GABAergic, Glutamatergic, Calcium Blockers, Sodium Blockers
110 Participants Needed
Telehealth for Lewy Body Dementia
Gainesville, Florida
Lewy body dementia (LBD) is the 2nd most common neurodegenerative dementia in the US. Optimal care requires an interdisciplinary approach, however often faced barriers include rural residence, limited access to specialists, travel distance, limited awareness of resources, and physical, cognitive, and behavioral impairments making travel to appointments challenging. Delivering interdisciplinary care remotely using video technology has the potential to improve access to care for patients with LBD.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Severe Dementia, No Internet, Others
106 Participants Needed
Cranberry Juice for Cognitive Symptoms
Gainesville, Florida
This clinical trial aims to investigate the effects of a 70-day consumption of cranberry juice on cognitive and motor accuracy, mental and physiological stress, and stress response in healthy men and women between the ages of 30 and 55 who engage in multitasking. The trial will utilize a randomized, double-blinded, placebo-controlled design. It is worth noting that studies have shown that over half of middle-aged Americans experience stress, which can lead to cognitive decline and depression. Previous clinical trials have indicated that consuming polyphenol-rich foods can have positive effects on cognitive function in humans. However, no study to date has examined the long-term effects of cranberry juice consumption on cognitive performance, mental stress, and stress response specifically in individuals engaged in multitasking. Based on this gap in knowledge, the investigators hypothesize the following: (1) chronic consumption of cranberry juice will improve cognitive and motor accuracy, as well as mental and psychological stress responses in young adults subjected to intense multitasking. (2) cranberry juice consumption will alleviate the negative consequences of frequent intense multitasking, such as fatigue, mood fluctuations, cognitive impairment, and memory issues. Additionally, it is expected to have a positive impact on stress biomarkers and neurotransmitter levels. By conducting this clinical trial, the investigators aim to shed light on the potential benefits of cranberry juice consumption in improving cognitive performance, mitigating mental stress, and positively influencing stress responses in individuals who engage in intense multitasking.
Trial Details
Trial Status:Recruiting
Age:30 - 55
Key Eligibility Criteria
Disqualifiers:Not Listed
126 Participants Needed
Transcranial Pulse Stimulation for Dementia
Gainesville, Florida
This study will investigate transcranial pulse stimulation (TPS) as a method of enhancing cognitive and neural function. The study team will apply this low intensity, magnetically pulse technology to key brain regions in a randomized, sham-controlled trial (RCT). The study will determine the magnitude of changes in cognitive function and brain function and structure between a pre- and post-stimulation among 10 typically-aging older adults and 10 patients with mild dementia.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:65 - 84
Key Eligibility Criteria
Disqualifiers:Neurological Disorders, Major Psychiatric Illness, Others
Must Not Be Taking:Sedatives, Anticholinergics, CNS Drugs
20 Participants Needed
Tau PET Imaging for Cognitive Impairment
Jacksonville, Florida
The researchers are trying to gather information and learn more about imaging tests in racially different people who are cognitively normal or have dementia.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:30+
Key Eligibility Criteria
Disqualifiers:Pregnancy, Claustrophobia, Prolonged QT, Others
240 Participants Needed
KarXT + KarX-EC for Alzheimer's Disease
Jacksonville, Florida
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:60 - 85
Key Eligibility Criteria
Disqualifiers:Hepatic Impairment, Major Depression, Schizophrenia, Others
Must Be Taking:Acetyl Choline Esterase Inhibitors, Memantine
586 Participants Needed
Deep Brain Stimulation for Alzheimer's Disease
Augusta, Georgia
The purpose of this study is to test a new procedure to treat Alzheimer's disease. The procedure is called intermittent Deep Brain Stimulation (DBS) of the nucleus basalis of Meynert. There will be up to six participants enrolled at Wellstar MCG Memory Clinic. There will be another six participants similarly enrolled to act as a control group that does not receive DBS. This second group will document the course of progression of Alzheimer's disease under the normal standard of care. The main goal of the study is to determine if DBS can sustain or improve cognition in Alzheimer's disease for at least two years. Participant data, with identifying information removed, may be shared with online repositories for comparison with trials with similar subjects.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:65 - 85
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Stroke, Others
Must Be Taking:Psychopharmacological Medication
12 Participants Needed
Anti-Diabetic Medications for Parkinson's Disease and Lewy Body Dementia
Jacksonville, Florida
The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:45 - 65
Key Eligibility Criteria
Disqualifiers:Renal Impairment, Bleeding Disorder, Pregnancy, Others
Must Be Taking:DPP4 Inhibitors, SGLT2 Inhibitors
18 Participants Needed
Know someone looking for new options?
Spread the word